Highly Purified Menotropin (HP-hMG) Versus Recombinant FSH (rFSH) Plus Recombinant LH (rLH) in Intrauterine Insemination Cycles in Women ≥35... | NCT01604044 | Trialant
CompletedInterventionalPhase 1Updated Sep 5, 2014
Highly Purified Menotropin (HP-hMG) Versus Recombinant FSH (rFSH) Plus Recombinant LH (rLH) in Intrauterine Insemination Cycles in Women ≥35 Years: a Prospective Randomized Trial.
ClinicalTrials.gov ID
NCT01604044
Lead Sponsor
Catholic University of the Sacred HeartOTHER
Overall Status
Completed
Study Type
Interventional
Phase
Phase 1
Enrollment
579Actual
Last Update Posted
Sep 5, 2014Estimated
Start Date
May 2012
Primary Completion Date
Sep 2013Actual
Completion Date
Sep 2013Actual
Brief Summary
This study evaluates the effects of different therapies in ovulation induction in Intrauterine Insemination Cycles.
Female Infertility
Meropur 150 a day
Gonal-f 150 plus Luveris 150
Ages Eligible for Study
Adult (18-64)
Sexes Eligible for Study
Female
Accepts Healthy Volunteers
Yes
Eligibility Criteria
Inclusion Criteria:
women with story of infertility sine causa and mild-moderate male factor
regular ovulatory menstrual cycles
BMI ≤27 kg/m2
normal day 3 hormonal pattern
bilateral tubal patency
Exclusion Criteria:
mono/bilateral tubal occlusion,
severe male factor
polycystic ovarian syndrome or any systemic disease or endocrine or metabolic abnormalities
pelvic inflammatory disease
endometriosis
sexual organ malformations
neoplasms or breast pathology incompatible with gonadotropin stimulation.